1. Home
  2. ROMA vs TTRX Comparison

ROMA vs TTRX Comparison

Compare ROMA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$2.24

Market Cap

133.4M

Sector

Finance

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.74

Market Cap

121.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ROMA
TTRX
Founded
2018
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.4M
121.3M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
ROMA
TTRX
Price
$2.24
$3.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
954.1K
42.3K
Earning Date
03-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,640,101.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
59.60
N/A
52 Week Low
$0.58
$2.57
52 Week High
$8.88
$26.50

Technical Indicators

Market Signals
Indicator
ROMA
TTRX
Relative Strength Index (RSI) 50.24 39.04
Support Level $1.82 $3.96
Resistance Level $8.88 $5.02
Average True Range (ATR) 1.32 0.35
MACD -0.00 -0.14
Stochastic Oscillator 13.14 13.60

Price Performance

Historical Comparison
ROMA
TTRX

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: